(Total Views: 602)
Posted On: 03/05/2020 11:21:07 AM
Post# of 72441
There was a quote from IPIX management that a shareholder who was at last September’s shareholder meeting noted in regards to B-IBD Oral, where IPIX management stated “BP wants to see a 2a. BP told us that if we can show them a successful 2a, they will be “knocking our door down.” I am assuming that today’s announced phase2 is being directed by at least one of those interested parties.
The description of the trial is “To assess efficacy and safety of oral Brilacidin in active UC across 6 weeks”. 6 weeks is not a very long trial and therefore should not be an expensive trial. IMO this duration and targeted outcomes are being directed by an interested partner.
IMO IPIX has funding identified for this trial for it to be PRed today. Note the difference in the language regarding IPIX proceeding with this B-IBD Oral for Colitis vs the language regarding IPIX’s plans on proceeding with B-OM:
“The Company is presently interviewing Contract Research Organizations for site selection with the understanding that the goal is to initiate the trial this summer.”
vs
The last several PR’s in the “About IPIX Section” in regards to B-OM stating “The Company plans to advance Brilacidin oral rinse into Phase 3 development, subject to available financial resources.” Note that today’s B-IBD Oral phase 2 announcement did not have this caveat.
Connecting the dots it appears to me that IPIX is proceeding with a B-IBD Oral Phase 2 with direction from an interested party and/or parties. IMO IPIX has funding identified to move this 6 week trial to completion with a targeted partnership deal to follow. This deal IMO will be substantial as it positions B-IBD Oral a phase 3 away from capturing a meaningful percentage of a $48B IBD market that has a major need of an oral solution with high efficacy and safety profile. This initiative alone represents huge shareholder value but adding in a B-OM partnership along with major interest in Brilacidin as a treatment for the coronavirus, 2020 should be the beginning of great shareholder value and wealth.
The description of the trial is “To assess efficacy and safety of oral Brilacidin in active UC across 6 weeks”. 6 weeks is not a very long trial and therefore should not be an expensive trial. IMO this duration and targeted outcomes are being directed by an interested partner.
IMO IPIX has funding identified for this trial for it to be PRed today. Note the difference in the language regarding IPIX proceeding with this B-IBD Oral for Colitis vs the language regarding IPIX’s plans on proceeding with B-OM:
“The Company is presently interviewing Contract Research Organizations for site selection with the understanding that the goal is to initiate the trial this summer.”
vs
The last several PR’s in the “About IPIX Section” in regards to B-OM stating “The Company plans to advance Brilacidin oral rinse into Phase 3 development, subject to available financial resources.” Note that today’s B-IBD Oral phase 2 announcement did not have this caveat.
Connecting the dots it appears to me that IPIX is proceeding with a B-IBD Oral Phase 2 with direction from an interested party and/or parties. IMO IPIX has funding identified to move this 6 week trial to completion with a targeted partnership deal to follow. This deal IMO will be substantial as it positions B-IBD Oral a phase 3 away from capturing a meaningful percentage of a $48B IBD market that has a major need of an oral solution with high efficacy and safety profile. This initiative alone represents huge shareholder value but adding in a B-OM partnership along with major interest in Brilacidin as a treatment for the coronavirus, 2020 should be the beginning of great shareholder value and wealth.
(16)
(0)Scroll down for more posts ▼
